The Cooper Companies, Inc. (NASDAQ:COO) Shares Acquired by Navellier & Associates Inc.

Navellier & Associates Inc. grew its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 30.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,168 shares of the medical device company’s stock after buying an additional 975 shares during the quarter. Navellier & Associates Inc.’s holdings in Cooper Companies were worth $383,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of COO. Ashton Thomas Securities LLC acquired a new position in shares of Cooper Companies in the 3rd quarter valued at about $25,000. Byrne Asset Management LLC purchased a new position in shares of Cooper Companies in the 4th quarter valued at about $33,000. Covestor Ltd increased its stake in shares of Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 200 shares in the last quarter. Brown Brothers Harriman & Co. increased its stake in shares of Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 275 shares in the last quarter. Finally, West Financial Advisors LLC purchased a new position in shares of Cooper Companies in the 4th quarter valued at about $49,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Price Performance

COO stock opened at $88.48 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The business has a 50 day simple moving average of $92.94 and a 200-day simple moving average of $99.66. The firm has a market capitalization of $17.66 billion, a PE ratio of 45.37, a price-to-earnings-growth ratio of 2.25 and a beta of 1.00. The Cooper Companies, Inc. has a 1 year low of $84.76 and a 1 year high of $112.38.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business’s revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.87 earnings per share. Equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COO has been the subject of several recent analyst reports. Morgan Stanley cut their price target on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research note on Friday, December 6th. StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Citigroup cut their price target on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Finally, Wells Fargo & Company boosted their price objective on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.